Publications by authors named "Sami Diab"

Claim this Profile
S
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, Kathleen Moore, Ana Oaknin, Sami Diab

Int J Gynecol Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study.
Sara M Tolaney, Kevin Kalinsky, Virginia G Kaklamani, David R D'Adamo, Gursel Aktan, Sami Diab

Clin Cancer Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Sara A Hurvitz, Sara M Tolaney, Delphine Loirat, Kevin Punie, Sami Diab

N Engl J Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
Sara A Hurvitz, Anthony Gonçalves, Hope S Rugo, Kyung-Hun Lee, Louis Fehrenbacher, Sami Diab

Oncologist· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.
Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Sami Diab

JNCI Cancer Spectr· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Denise A Yardley, Lowell Hart, Anne Favret, Sibel Blau, Sami Diab

Clin Breast Cancer· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
Joyce O'Shaughnessy, Angela DeMichele, Cynthia X Ma, Paul Richards, Denise A Yardley, Sami Diab

Breast Cancer Res Treat· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
Wolfgang Janni, Emilio Alba, Thomas Bachelot, Sami Diab, Miguel Gil-Gil

Breast Cancer Res Treat· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of race and tumor subtype on second malignancy risk in women with breast cancer.
Nicholas Diab, Gary Clark, Lucy Langer, Yunfei Wang, Barbara Hamlington, Sami Diab

Springerplus· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
Normand Blais, D Ross Camidge, Derek J Jonker, Denis Soulières, Scott A Laurie, Sami G Diab

Invest New Drugs· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
Donald Richards, Darren M Kocs, Alexander I Spira, A David McCollum, Sami Diab

Eur J Cancer· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
Qing Zhou, Daniel Gustafson, Sujatha Nallapareddy, Sami Diab, Stephen Leong

Invest New Drugs· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Jennifer L Spratlin, Roger B Cohen, Matthew Eadens, Lia Gore, D Ross Camidge, Sami Diab

J Clin Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
Stephen Leong, Roger B Cohen, Daniel L Gustafson, Corey J Langer, D Ross Camidge, Sami Diab

J Clin Oncol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Breast cancer in elderly].
Sami G Diab

Med Sci (Paris)· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Bahram Forouzesh, Chris H Takimoto, Andrew Goetz, Sami Diab, Lisa A Hammond

Clin Cancer Res· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado.
Lisa G Mullineaux, Teresa M Castellano, Jeffrey Shaw, Lisen Axell, Marie E Wood, Sami Diab

Cancer· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis